Northwestern University

Massachusetts Institute of Technology

Vesseltek Biomedical LLC

Guillermo A Ameer

Jian Yang

Melina R Kibbe

Robert Van Lith

Robert Samuel Langer

Cheng Sun

Bin Jiang

Antonio Roy Webb

Jason A Wertheim

Hongjin Qiu

Michele Jen

Haichao Zhao

Hidde L Ploegh

Yadong Wang

Milan Mrksich

Evan A Scott

Maria Ann Rupnick

Henry Oliver Tenadooah Ware

Congwen Duan

Paul D Puglisi

Kyle Koss

Jisheng Xiao

Eric T Crumpler

Simona Morochnik

Yunxiao Zhu

Evan C Baker

Henry O T Ware

Zdravka Cankova

Fan Zhou

Vinit N Varu

Eric Grovender

Antonio Webb

Rober S Langer, Jr

Jacqueline A Burke

Banu Akar

Henry Oliver T Ware

Helena Freire Haddad

Provided herein photo-reactive inks, thermal-curable materials and objects (e.g., medical implants, scaffolds, devices, etc.) made therefrom, and methods of preparation and use thereof.

3D-printed bioresorbable all-polymer composite soft tissue scaffolds

Photo-reactive inks and thermal-curable materials made therefrom

Provided herein are intravascular retrievable cell delivery systems and methods of use thereof for cell transplantation.

Intravascular retrievable cell delivery system

Disclosed are heparin conjugates comprising heparin conjugated to a peptide that binds to a protein of the extracellular matrix (ECM) of cellular tissue, such as a collagen-binding peptide that binds to collagen of the ECM. The disclosed heparin conjugates may be utilized in methods that include treating ECM material to incorporate the heparin conjugates and impart anticoagulant activity to the ECM. The disclosed heparin conjugates also may be formulated as pharmaceutical compositions for treating and/or preventing vascular injuries and conditions.

Heparin conjugated to collagen-binding peptides for targeting to biological and synthetic tissues

The present invention provides methods of making an in vivo animal model for detecting anti-poly(ethylene glycol) (PEG) antibodies. The methods of the disclosure comprises administering subcutaneously to an animal model a composition comprising antibodies against poly(ethylene glycol) chains with a molecular weight of at least 550 Da to maintain an anti-PEG antibody level within the animal model. The in vivo animal model can be used for testing and screening drugs and other compositions for adverse reactions, bioavailability, and immunogenicity prior to administration to a human subject.

Anti-polyethylene glycol (PEG) antibody mouse model for rigorous assessment of PEG-based therapies

Provided herein are thermoresponsive polymer materials and methods of preparation and use thereof. In particular, materials are provided that cure upon exposure to physiologic conditions (e.g., human body temperature) and find use in, for example, orthopedic surgery, bone tissue engineering, and the repair of bone injuries and defects.

Body temperature-triggered, in situ forming biomaterials and devices

Provided herein are methods, compositions, devices, and systems for the 3D printing of biomedical implants. In particular, methods and systems are provided for 3D printing of biomedical devices (e.g., endovascular stents) using photo-curable biomaterial inks (e.g., or methacrylated poly(diol citrate)).

3D printing of biomedical implants

Provided herein are injectable, thermoresponsive hydrogels that are liquid at room temperature, provide a carrier material, and gel at body temperature to allow for controlled release. In particular, PPCN-based hydrogels are provided with therapeutic agents (e.g., drugs, ions, etc.) incorporated within or appended thereto, and methods of preparation and use thereof, for example, for the promotion of bone formation/repair and/or the treatment of bone diseases.

Bone-promoting thermoresponsive macromolecules

Compositions and methods are provided for improved wound healing. In particular, provided herein are compositions and methods for the direct delivery of Sirtuin-1 (Sirt1) or vectors encoding Sirt1 to the wounds (e.g., of diabetic patients).

Wound healing through sirt1 overexpression

Provided herein are compositions, devices, and systems comprising copolymers of an N-alkyl acrylamide residue and a polyester comprising citric acid, polyethylene glycol, and glycerol 1,3-diglycerolate diacrylate, and methods of use and manufacture thereof.

Injectable thermoresponsive polyelectrolytes

Compositions and methods are provided for improved wound healing. In particular, provided herein are compositions and methods for the direct delivery of Sirtuin-1 (Sirt1) or vectors encoding Sirt1 to the wounds (e.g., of diabetic patients). In some embodiments, provided herein are therapeutic devices comprising: (a) a vector encoding Sirtuin-1 (Sirt 1); and (b) a hydrogel carrier. In some embodiments, the vector comprises a viral vector comprising a polynucleotide sequence encoding Sirt 1. In some embodiments, the vector comprises a non-viral vector comprising a polynucleotide sequence encoding Sirt1.

Retroviral particles expressing Sirt1 embedded within PPCN

Provided herein are polymer and metal organic frameworks (MOFs) composites, and methods of use and preparation thereof. In particular, Poly(polyethyleneglycol citrate-co-N-isopropylacrylamide) (PPCN) and copper MOF composites are provided.

Polymer metal-organic framework composites

Provided herein are materials for the promotion of tissue regeneration, and methods of promoting tissue regeneration and wound healing therewith. In particular, materials displaying laminin-derived peptide sequences that facilitate cell migration into the material, and methods of use thereof, are provided.

Materials for tissue regeneration

Provided herein are bioactivated polymer/extracellular matrix (ECM) composites and methods of preparation and use thereof. In particular, heparinized cysteine-polymer/ECM composites, and methods of preparation and use thereof, are provided. In some embodiments, provided herein are compositions comprising a composite of: (a) extracellular matrix (ECM), and (b) a polyester covalently linked to a bioactive agent. In some embodiments, the composite is a homogeneous composite. In some embodiments, the ECM is decellularized ECM. In some embodiments, the ECM is not substantially crosslinked.

Thromboresistant-anticoagulant extracellular matrix

Provided herein are compositions comprising panthenol-citrate containing materials. In particular, panthenol citrate compounds, oligomers, and polymers, and methods of use and synthesis thereof, are provided herein. Panthenol-citrate containing materials are a class of nontoxic, photoluminescent-chromophore-containing compounds, oligomers, and polymers with high absorption in the UVA and UVB range that can be incorporated and/or engineered into a variety of optically-active biomaterials (e.g., sunscreen products).

Growing community of inventors

Chicago, IL, United States of America

Guillermo A Ameer